Wolfe Research initiated coverage on Exact Sciences with a new price target
$EXAS
Medical Specialities
Health Care
Wolfe Research initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $95.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $60.00 | Outperform | Mizuho |
| 3/13/2025 | $52.00 | Sector Perform | RBC Capital Mkts |
| 1/23/2025 | $70.00 | Overweight | Barclays |
| 8/28/2024 | $75.00 | Overweight | Wells Fargo |
| 6/27/2024 | $70.00 | Sector Outperform | Scotiabank |
| 6/3/2024 | $75.00 | Buy | Jefferies |
| 1/2/2024 | $91.00 | Hold → Buy | The Benchmark Company |
| 12/14/2023 | $90.00 | Buy | Guggenheim |
8-K - EXACT SCIENCES CORP (0001124140) (Filer)
SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)
10-Q - EXACT SCIENCES CORP (0001124140) (Filer)
Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00
RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00
Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00
First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod
Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic
4 - EXACT SCIENCES CORP (0001124140) (Issuer)